Cite
HARVARD Citation
Cohen, J. et al. (2022). A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple sclerosis. pp. 817-830. [Online].